AstraZeneca Reports Positive Trial Results for Cancer Drug Lynparza
October 26 2016 - 1:53AM
Dow Jones News
By Tapan Panchal
LONDON--AstraZeneca PLC (AZN.LN) Wednesday reported positive
trial results for Lynparza, drug used for the treatment of ovarian
cancer.
The pharmaceutical company said phase III SOLO-2 trial of
Lynparza tablets, 300 milligrams twice daily, demonstrated a
clinically-meaningful and statistically-significant improvement of
progression-free survival among patients.
"We will work with regulatory authorities to make Lynparza
tablets available as quickly as possible to patients with ovarian
cancer. We remain committed to investigating the full potential of
Lynparza, both as monotherapy and in combinations, and to
identifying all patients who may benefit from this important
medicine," said AstraZeneca's Chief Medical Officer and Executive
Vice President for Medicines Development Sean Bohen.
Write to Tapan Panchal at tapan.panchal@wsj.com
(END) Dow Jones Newswires
October 26, 2016 02:38 ET (06:38 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jan 2025 to Feb 2025
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Feb 2025
